Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity
Aleix Prat(Hospital Clínic de Barcelona), Javier Cortés(Villa Maria Hospital), Josep Tabernero(Deaconess Hospital), Vicente Peg(Instituto de Salud Carlos III), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Shaheenah Dawood(Dubai Hospital), Patricia Galván(Vall d'Hebron Institute of Oncology), Ana Vivancos(Vall d'Hebron Institute of Oncology), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Santiago Ramón y Cajal(Instituto de Salud Carlos III), Enriqueta Felip(Institut Català d'Ornitologia), Héctor G. Pálmer(CIBBIM-Nanomedicine), Cheng Fan(University of North Carolina at Chapel Hill), María Vidal(Inserm), J.M. del Campo(Vall d'Hebron Hospital Universitari), Bárbara Adamo(Hospital Clínic de Barcelona)
Cited by 56
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k